Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline B Hall

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 3, 2003
Transmission of influenza: implications for control in health care settingsCarolyn Buxton Bridges, Matthew J Kuehnert, Caroline B Hall
Current Topics in Microbiology and Immunology|December 24, 2013
Clinical and epidemiologic features of respiratory syncytial virusCaroline B Hall, Eric A F Simőes, Larry J Anderson
Journal of Medical Economics|February 5, 2010
Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of lifeMichael L Forbes, Caroline B Hall, Anne Jackson, et al.
Pediatrics|January 28, 2009
Persistence of morbidity and cost differences between late-preterm and term infants during the first year of lifeKimmie K McLaurin, Caroline B Hall, E Anne Jackson, et al.
Archives of Pediatrics & Adolescent Medicine|October 5, 2006
Cost-effectiveness analysis of palivizumab in premature infants without chronic lung diseaseNahed O Elhassan, Melony E S Sorbero, Caroline B Hall, et al.
The Pediatric Infectious Disease Journal|November 14, 2003
Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?Nahed O Elhassan, Timothy P Stevens, Melony E Sorbero, et al.
Current Medical Research and Opinion|July 30, 2010
Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy childrenRobert C Welliver, Paul A Checchia, Jay H Bauman, et al.
Journal of Medical Economics|April 29, 2011
Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infantsNianwen Shi, Liisa Palmer, Bong-Chul Chu, et al.
Pediatric Pulmonology|July 16, 2010
Healthcare costs within a year of respiratory syncytial virus among Medicaid infantsLiisa Palmer, Caroline B Hall, Julie P Katkin, et al.
Current Medical Research and Opinion|January 4, 2011
Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infantsLiisa Palmer, Caroline B Hall, Julie P Katkin, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 3, 2003
Transmission of influenza: implications for control in health care settingsCarolyn Buxton Bridges, Matthew J Kuehnert, Caroline B Hall
Current Topics in Microbiology and Immunology|December 24, 2013
Clinical and epidemiologic features of respiratory syncytial virusCaroline B Hall, Eric A F Simőes, Larry J Anderson
Journal of Medical Economics|February 5, 2010
Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of lifeMichael L Forbes, Caroline B Hall, Anne Jackson, et al.
Pediatrics|January 28, 2009
Persistence of morbidity and cost differences between late-preterm and term infants during the first year of lifeKimmie K McLaurin, Caroline B Hall, E Anne Jackson, et al.
Archives of Pediatrics & Adolescent Medicine|October 5, 2006
Cost-effectiveness analysis of palivizumab in premature infants without chronic lung diseaseNahed O Elhassan, Melony E S Sorbero, Caroline B Hall, et al.
The Pediatric Infectious Disease Journal|November 14, 2003
Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?Nahed O Elhassan, Timothy P Stevens, Melony E Sorbero, et al.
Current Medical Research and Opinion|July 30, 2010
Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy childrenRobert C Welliver, Paul A Checchia, Jay H Bauman, et al.
Journal of Medical Economics|April 29, 2011
Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infantsNianwen Shi, Liisa Palmer, Bong-Chul Chu, et al.
Pediatric Pulmonology|July 16, 2010
Healthcare costs within a year of respiratory syncytial virus among Medicaid infantsLiisa Palmer, Caroline B Hall, Julie P Katkin, et al.
Current Medical Research and Opinion|January 4, 2011
Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infantsLiisa Palmer, Caroline B Hall, Julie P Katkin, et al.
Pageof 5